Marburg, Germany

Jürgen Lindner


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Jürgen Lindner and His Contributions to Nucleotide Synthesis Inhibitors

Introduction: Jürgen Lindner, an accomplished inventor based in Marburg, Germany, has made significant strides in the field of nucleotide synthesis inhibitors. With a singular patent to his name, Lindner's work showcases the potential for innovative solutions in the treatment of immunological diseases.

Latest Patents: Lindner's patent, titled "Method for finding nucleotide synthesis inhibitors having fewer side effects," pertains to an advanced method for identifying nucleotide synthesis inhibitors that offer a more favorable therapeutic window. The method involves administering an efficacious dose of a nucleotide synthesis inhibitor to a mammal, subsequently monitoring the concentration of the inhibitor in the mammal's bloodstream. A key aspect of the innovation is determining whether the inhibitor has a shorter half-life compared to existing compounds, specifically N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. This groundbreaking patent highlights the potential for creating more effective treatments for immunological disorders with reduced side effects.

Career Highlights: Jürgen Lindner is actively employed at Aventis Pharma Deutschland GmbH, a prominent player in the pharmaceutical industry. His research and innovative approach have contributed significantly to the company's efforts in developing novel therapeutic options.

Collaborations: Throughout his career, Lindner has collaborated with several industry experts, including his coworker Burkhard Haase. Their partnership demonstrates the power of teamwork in bolstering research capabilities and enhancing the development of breakthrough solutions in healthcare.

Conclusion: Jürgen Lindner's contributions to the field of nucleotide synthesis inhibitors reflect a commitment to advancing medical science. His innovative patent holds promise for improving therapies for immunological diseases, ultimately benefiting patients with a safer, more effective treatment regimen. As he continues his work at Aventis Pharma Deutschland GmbH, the impact of his innovations is poised to resonate within the biomedical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…